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Abstract
Several arenaviruses can cause viral hemorrhagic fever, a severe disease with case-fatality rates in hospitalized individuals
ranging from 15-30%. Because of limited prophylaxis and treatment options, new medical countermeasures are needed for
these viruses classified by the National Institutes of Allergy and Infectious Diseases (NIAID) as top priority biodefense Category
A pathogens. Recombinantconsensus interferon alpha(cIFN-a) is a licensed protein with broad clinical appeal. However,while
cIFN-a has great therapeutic value, its utility for biodefense applications is hindered by its short in vivo half-life, mode and
frequency of administration, and costly production. To address these limitations, we describe the use of DEF201, a replication-
deficient adenovirus vector that drives the expression of cIFN-a, for pre- and post-exposure prophylaxis of acute arenaviral
infection modeled in hamsters. Intranasal administration of DEF201 24 h prior to challenge with Pichinde ´ virus (PICV) was
highly effective at protecting animals from mortality and preventing viral replication and liver-associated disease. A significant
protective effect was still observed with a single dosing of DEF201 given two weeks prior to PICV challenge. DEF201 was also
efficacious when administered as a treatment 24 to 48 h post-virus exposure. The protective effect of DEF201 was largely
attributed to the expression of cIFN-a, as dosing with a control empty vector adenovirus did not protect hamsters from lethal
PICV challenge. Effective countermeasures that are highly stable, easily administered, and elicit long lasting protective
immunity are much needed for arena and other viral infections. The DEF201 technology has the potential to address all of
these issues and may serve as a broad-spectrum antiviral to enhance host defense against a number of viral pathogens.
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Introduction
The Arenaviridae family of viruses has several members that can
cause viral hemorrhagic fever, an acute, often-fatal, viral syndrome
characterized by intensefever, malaise, and lessfrequently, bleeding
and neurologic manifestations. Case fatality rates of hospitalized
patients suffering from arenaviral hemorrhagic fever (AHF) range
from 15–30% [1,2,3,4]. Arenaviruses known to cause AHF include
Junı ´n, Machupo, Guanarito, Sabia ´, and Chapare in the South
American continent, and Lassa and Lujo in west and southern
Africa, respectively. Primary transmission of the arenaviruses from
respective rodent reservoir hosts to humans occurs via exposure to
contaminated excreta [5]. Person-to-person transmission can occur
through contact with blood or other body fluids during the care and
management of infected individuals [1,6]. Notably, these viruses are
considered a threat to national security and are classified as highest
priority pathogens by the NIAID [7].
At present, the treatment of AHF is limited to ribavirin and
immune plasma [8,9]. The latter has only been proven to be
effective in treating cases of Argentine hemorrhagic fever (Junı ´n
virus infection) within 8 days of disease onset. Off-label usage of
ribavirin has been shown to be effective in treating Lassa fever
when therapy was initiated within 6 days of the development of
clinical symptoms. However, there are toxicities associated with
ribavirin therapy at dosages required for efficacious use, which
may contribute to the observed poor patient compliance in
completing prescribed treatment regimens [10,11]. Very limited
case data using ribavirin to treat other AHFs supports the use of
emergency protocols [1,12,13], however the utility of ribavirin
therapy remains to be seen.
Interferon alpha (IFN-a) is an effective part of the host innate
immune response, which can be manufactured as a recombinant
human protein with broad clinical appeal [14]. Consensus (c)IFN-
a, also known as IFN alfacon-1 and Infergen, is a licensed, second
generation IFN-a engineered to contain the most frequently
occurring amino acids among the nonallelic IFN-a subtypes.
Previously, we have demonstrated that cIFN-a can be used
effectively alone, or in combination with ribavirin, to treat
Pichinde ´ virus (PICV) infection in hamsters [15,16], an experi-
mental model of acute arenaviral disease [17]. However, while
cIFN-a has clinical value, its usefulness is hindered by its short
half-life and cost to manufacture. There is an initial distributive
half-life of 7 minutes and a beta half-life of 2 to 5 hours [14]. The
rapid systemic clearance requires frequent dosing to achieve
desired therapeutic levels. Consequently, treatment can result in
well-documented toxicities which include headache, depression,
hair loss, fever, and malaise. In order to combat the rapid
degradation, PEGylated forms of recombinant IFN-a have been
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hours, thus reducing the number of injections to once per week
[18]. However, the cost to manufacture PEG-IFN-a is exceedingly
high, and the PEGylation process has been shown to reduce the
activity of IFN-a, thereby further increasing the production costs.
To circumvent the fast decay of cIFN-a, a replication-
incompetent, recombinant adenovirus type 5 (rAd5) gene delivery
platform was designed to drive constitutive expression of the cIFN-
a gene from transduced nasal epithelial target cells. This rAd5
cIFN-a virus, called DEF201, was first developed in mice and
recently shown to be active against yellow fever virus (YFV)
infection in hamsters [19,20]. The intranasal (i.n.) inoculation used
in the YFV study prevents the host immune system from
recognizing the Ad5 vector, thereby bypassing any possible pre-
existing immunity [21]. In the present study, we evaluated the use
of DEF201 administered i.n. for the prevention and treatment of
PICV infection in hamsters.
Materials and Methods
Ethics statement
All animal procedures complied with USDA guidelines and
were conducted at the AAALAC-accredited Laboratory Animal
Research Center at Utah State University under protocol 1229,
approved by the Utah State University Institutional Animal Care
and Use Committee.
Animals
Female golden Syrian hamsters were obtained from Charles
River Laboratories (Wilmington, MA) and acclimated for a
minimum of 6 days prior to experimentation. They were fed
standard hamster chow and tap water ad libitum. Animals were
approximately 7–9 weeks old at the time of virus challenge.
Viruses
PICV, strain An 4763, was provided by Dr. David Gangemi
(Clemson University, Clemson, South Carolina). The virus was
passaged once through hamsters. Virus stocks were prepared from
pooled livers harvested from infected hamsters. Virus dilutions
were made in minimal essential medium (MEM), and infectious
inoculum was given bilaterally in two intraperitoneal (i.p.)
injections of 0.1 mL each. The recombinant adenovirus vectored
cIFN-a (rAd5-huIFN-a; DEF201) and the rAd5 empty vector (rAd
EV) control virus were provided by Defyrus, Inc. (Toronto, ON,
Canada) at a concentration of 6610
9 and 2610
11 plaque-forming
units (pfu)/ml, respectively. Both viruses were prepared in PBS for
i.n. instillation in a 200 ml volume.
Liver, spleen and serum virus titers
Virus titers were assayed using an infectious cell culture assay as
previously described [22]. Briefly, a specific volume of liver or
spleen homogenate or serum was serially diluted and added to
triplicate wells of Vero (African green monkey kidney; American
Type Culture Collection, Manassas, VA) cell monolayers in 96-
well microplates. The viral cytopathic effect (CPE) was determined
7 to 8 days post-virus inoculation, and the 50% endpoints were
calculated as described [23]. The assay detection ranges were 2.8
to 9.5 log10 50% cell culture infectious doses (CCID50)/g of liver
or spleen and 1.8 to 8.5 log10 CCID50/ml of serum. In samples
presenting with undetectable liver or spleen virus, a value of ,2.8
was assigned (,1.8 for serum). Conversely, in cases wherein virus
exceeded the detection range, a value of.9.5 (.8.5 for serum) was
assigned. For statistical analysis, values of 2.8 or 9.5 log10 (1.8 or
8.5 for serum) were assigned as needed for samples with
undetectable or saturated virus levels, respectively.
Serum alanine aminotransferase (ALT) determinations
Detection of ALT in serum is an indirect method for evaluating
liver disease. Serum ALT levels were measured using the ALT
(SGPT) Reagent Set purchased from Pointe Scientific, Inc.
(Lincoln Park, MI) per the manufacturer’s recommendations.
The reagent volumes were adjusted for analysis on 96-well
microplates.
Experimental design
DEF201 dose range titration experiment. Hamsters were
weighed on the morning prior to the day of infection and grouped
(n=15 for drug treatment groups, 26 for the placebo group) so
that the average hamster weight per group across the entire
experiment varied by less than 5 grams. Varying pfu amounts of
DEF201, the rAd EV control virus, or saline placebo treatments
were administered in a single i.n. dose 24 h prior to challenge with
,5 pfu of PICV. Five animals from each group were sacrificed on
day 7 of infection. Serum was collected for assaying ALT activity,
and virus titers were determined for liver, spleen, and serum
samples as described above. The remaining 10 animals (21 for the
placebo group) were observed 21 days for mortality and weighed
individually every 3 days starting on day 0. Sham-infected normal
controls (n=3) were included for comparison.
Extended pre-exposure prophylaxis experiment. The
design was similar to the DEF201 titration experiment with the
following differences. Hamsters were weighed on the morning of
initial pretreatment (day 214 relative to the infection) and grouped
(n=15 per group). Groups were treated once i.n. with 10
8 pfu of
Figure 1. DEF201 pretreatment protects PICV-infected ham-
sters from mortality. Animals were treated 24 hours prior to
infection with a single i.n. instillation of the indicated dose of DEF201,
the rAd EV control virus, or PBS placebo. (A) Survivial and (B) average
weights and standard deviations of surviving animals (measured every
3
rd day) are shown. ***P,0.001 compared to placebo-treated animals.
bP,0.01 and
cP,0.001 compared to rAd EV-treated animals.
doi:10.1371/journal.pone.0026072.g001
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given 14 or 7 days prior to challenge with ,5 PFU of PICV.
Animals were observed for 28 days post-challenge for mortality.
Post-exposure prophylaxis experiment. The design was
similar to the DEF201 pre-exposure prophylaxis experiment with
the following differences. Single dose i.n. treatments with 10
8 pfu
of DEF201 or rAd EV were administered 24 h prior to, or 6, 24,
or 48 h after challenge with ,5 pfu of PICV. On day 28 post-
infection, the surviving animals (including 6 naı ¨ve sham-infected
controls) were re-challenged. Morbidity and mortality were
observed out to 58 days after the initial challenge.
Statistical analysis
Kaplan-Meier survival plots and all statistical evaluations were
done using Prism (GraphPad Software, CA). The log-rank test was
used for survival analysis. For analyzing differences in viral titers,
ALT levels, and weight change, a one-way analysis of variance
(ANOVA) with Newman-Keuls post test or the Kruskal-Wallis
(two-tailed) test with the Dunn’s post test was performed based on
Gaussian distribution of the data.
Results
DEF201 protects hamsters from lethal PICV challenge
In the initial trial, hamsters were treated with 10
6 to 10
8 pfu of
DEF201 one day prior to challenge with a lethal dose of PICV.
Pretreatment with the highest dose of 10
8 pfu of DEF201 resulted
in 100% survival, and 10
7 and 10
6 pfu doses also significantly
protected 90% and 60% of hamsters, respectively, from mortality
(Figure 1A). Moreover, the hamster that succumbed in the 10
7
group, survived 19 days. Importantly, only one out of ten hamsters
treated with 10
8 pfu of the control rAd EV virus survived the
infection; however, there did appear to be a slight delay in the time
to death in the hamsters that received the control virus treatment.
The weights of the hamsters were measured every 3 days to
assess weight gain over the course of the experiment as a marker of
well being (Figure 1B). Notably, from day 3 to day 6, a time before
weight loss due to illness from PICV infection would have been
expected, hamster weights decreased as the dose of DEF201
increased. This would suggest that the higher treatment doses may
have resulted in some loss of appetite, probably due to mild illness
due to expression of consensus IFN since no overt effects were
noticeable when handling the animals. The hamsters that received
the 10
6 pfu dose of DEF201 gained weight through day 6 similarly
to the animals treated with saline placebo and the normal controls
(sham-infected, untreated) (Figure 1B). The high-dose of rAd EV
control virus also resulted in a slight reduction in weight compared
to the controls, suggesting that the immune response to the
adenoviral vector alone may have caused some malaise in the
animals.
There was no elevation in serum ALT levels on day 7 of infection
in samples collected from parallel treated and infected hamsters
Figure 2. DEF201 prophylaxis limits liver disease and viral loads in PICV-infected hamsters. Animals were treated as described in Figure 1
and sacrificed on day 7 of infection for analysis of serum (A) ALT and (B) virus titer, and (C) liver and (D) spleen viral titers. *P,0.05, **P,0.01,
compared to placebo-treated animals.
aP,0.05,
bP,0.01, compared to rAd EV-treated animals.
doi:10.1371/journal.pone.0026072.g002
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and 100% of the PBS placebo group had elevated levels of ALT,
reflective of liver disease. Interestingly, the 10
7 and 10
8 pfu DEF201
groups presented with little to no day-7 virus burden in the serum,
liver, or spleen, while the 10
6 group developed viral titers that were
comparable to the rAd EV and placebo controls (Figure 2B-D). A
delay in the development of liver disease in the 10
6 pfu DEF201-
treated animals may explain the reduced ALT levels. Alternatively,
saturation of liver virus titers in the low-dose DEF201, rAd EV, and
placebo groups may have masked a substantial difference between
the former and the viral vector and vehicle control groups.
DEF201 extended prophylaxis against PICV infection
We next evaluated the prophylactic window of protection
against PICV infection using the 10
8 pfu dose of DEF201.
Animals were treated one or two weeks prior to challenge with a
lethal dose of PICV. Consistent with the trend observed in initial
dose titration study, hamsters treated with the 10
8 pfu dose of
DEF201 had significantly reduced weights compared to those that
received the rAd EV and placebo control treatments (Figure 3A).
Nevertheless, the pretreatment with DEF201 seven days before
infection was highly protective (90% survival rate; Figure 3B).
Notably, the single hamster that failed to survive the challenge
succumbed on day 5, which was several days before the mean time
to death measured in both the placebo and rAd EV groups. An
autopsy to determine the cause of death was not performed.
In hamsters treated two-weeks prior to PICV challenge,
DEF201 significantly reduced mortality (50% survival) and
extended the time of death in the animals that succumbed
(Figure 3C). In contrast, uniform lethality was seen with animals
that received the rAd EV and placebo treatments. Of the 5
surviving animals pre-treated with DEF201, one was anorexic at
the conclusion of the study on day 28 post-infection. This was
reflected by a 27% weight loss compared to the animals starting
weight. It is possible that this hamster, which appeared ill and
lethargic, was not able to completely prevent the infection. It was
unclear whether it would have ultimately recovered if the
observation period had been extended.
On both the 7-day (Figure 4A, C, E, G) and 14-day (Figure 4B,
D, F, H) pretreatments, DEF201 significantly reduced day-7 viral
loads and liver disease (ALT) compared to the controls. The
absence of elevated ALT levels in the DEF201-treated hamsters
may be explained by the 2–3 log10 reduction in liver virus burden
(Figure 4E, F) and a delay in the development of liver disease.
Although tissue titers were slightly lower when DEF201 was given
7 days prior to challenge compared to the 14 day pretreatment,
this was not evident with serum viral burden. Because most
animals had measurable replicating PICV (Figure 4C–H), it is
likely that survivors would have been immunized and protected
from subsequent challenge. This may not be the case with
hamsters treated with DEF201 24 h prior to challenge since most
had no detectable virus titers in spleen, liver, or serum on day 7 of
PICV infection (Figure 2B–D).
DEF201 post-exposure prophylaxis and acquired
immunity against PICV re-challenge
Having observed dramatic protection when administered up to
2 weeks prior to challenge, a final experiment was conducted to
determine the therapeutic value of DEF201 in the hamster PICV
infection model. When DEF201 was administered 6 or 24 h after
challenge, highly significant protection was observed (Figure 5).
Efficacy waned when DEF201 treatment was delayed to 48 h post-
infection. As anticipated, the treatment given 24 pre-challenge
verified previous activity, with all animals surviving challenge.
Interestingly, there was higher than expected survival with the
control rAd EV treatments initiated 24 and 48 h post-challenge,
suggestive of a slight antiviral effect as the time of treatment was
further delayed (Figure 5).
The surviving hamsters from this experiment were re-chal-
lenged with PICV to assess the ability of DEF201 to enhance
longer-term protection via acquired immunity. With the exception
of 4 animals in the 24 h DEF201 pretreatment group, and a single
animal in the rAd EV 48 h group, all animals that were challenged
with PICV on day 0 of the experiment survived a second challenge
Figure 3. DEF201 extended pre-exposure prophylaxis protects
hamsters from lethal PICV challenge. Animals were treated i.n.
with a single dose 10
8 pfu of DEF201, the rAd EV control virus, or PBS
placebo 7 or 14 days prior to PICV infection. Animal weights were
measured two weeks prior to, and at the time of, PICV challenge. The
effect of 7-day and 14-day pretreatments on A) weight change over the
two-week period prior to PICV challenge and the extended PICV
prophylaxis efficacy data for the B) 7-day and C) 14-day pretreatments
are shown. ***P,0.001 compared to respective placebo-treated
animals.
bP,0.01,
cP,0.001 compared to respective rAd EV-treated
animals.
doi:10.1371/journal.pone.0026072.g003
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treated as described in Figure 3, 7 days (A, C, E, G) or 14 days (B, D, F, H) prior to PICV challenge, and sacrificed on day 7 of infection for analysis of
serum (A, B) ALT and (C, D) virus titers, and (E, F) liver and (G, H) spleen viral titers. *P,0.05, **P,0.01, ***P,0.001 compared to placebo-treated
animals.
aP,0.05,
bP,0.01,
cP,0.001 compared to rAd EV-treated animals.
doi:10.1371/journal.pone.0026072.g004
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infected succumbed as expected.
In animals that were sacrificed on day 7 relative to the first
infection, reductions in ALT and viral titers were most evident in
the groups that received DEF201 within 24 h of infection
(Figure 6). Notably, in the animals treated with the control rAd
EV, there was an interesting trend that developed with the 6 h
post-infection group having the greatest ALT levels and viral titers,
followed by the 24, 48, and 224 h groups. This trend may suggest
a low-level immune stimulation in the hamsters relative to the time
at which the rAd EV was given. The resulting lack of measurable
viral replication in the 224 h DEF201 group (Figure 6B–D) is
likely insufficient to elicit immunological memory. It is unclear as
to why one of the first infection survivors from the 48 h rAd EV
group ultimately succumbed to the second infection.
Discussion
In the present study, our findings demonstrate that expression of
cIFN-a following a single i.n. administration of DEF201 offers a
strong protective effect in hamsters against challenge with PICV
that included limiting liver disease and inducing an antiviral state
that inhibited systemic and tissue viral replication. The lack of
significant antiviral activity elicited by the rAd EV control virus
suggests that the enhanced antiviral response produced by
DEF201 is largely due to the expression of the cIFN-a gene.
The weak stimulatory effect seen in 1 of the 3 experiments was not
surprising considering the number of host systems that play a role
in sensing the adenovirus vector [24]; however, the effect was
short-lived. In contrast, the enhancement of the host antiviral
defenses by DEF201 was long-lasting with a 14-day pre-PICV
challenge prophylactic window. Moreover, DEF201 was effective
when given 1–2 days post-PICV infection. These data also suggest
that sufficient viral replication may be necessary to elicit an
adaptive immune response that confers lasting protective immu-
nity, as, for the most part, only re-challenged animals from the
24 h DEF201 pretreatment group succumbed to a second
challenge with a lethal PICV inoculum. Presumably, the robust
innate immunity and antiviral state induced by the DEF201
pretreatment rapidly controlled the ,5 pfu challenge dose
obviating the development of the adaptive immune response and
immunological memory.
The pathogenic arenaviruses have evolved strategies to suppress
and evade the host immune response [25,26,27,28], resulting in
uncontrolled replication and broad dissemination. However, they
appear to be unable to block the induction of IFN stimulated genes
via exogenous type I IFN [29], which may, in part, explain the
success of DEF201 and cIFN-a treatments [15]. Also essential to
the success of DEF201 was early intervention prior to significant
viral replication and engagement of innate immune suppressive
functions. Indeed, early induction of a strong type I IFN response
is associated with favorable disease outcome in nonhuman
primates challenged with Lassa virus [30]. Early post-exposure
prophylaxis was also required with exogenous cIFN-a protein
administered by the i.p. route [15,16]. With the multiple strategies
that arena and other pathogenic viruses have in place to subdue
the IFN-mediated host antiviral response [31], the utility of
DEF201, recombinant IFN proteins, and IFN inducing agents will
depend upon the nature of the IFN pathway blockade and require
early administration to be effective post-exposure.
Notably, with daily cIFN-a protein injections of up to 40 mg/kg,
significant protection was observed; however, survival rates did not
exceed 80% in those studies employing the same PICV hamster
model system and virus stock [15,16]. In contrast, DEF201
consistently elicited greater protection (90–100%). The improved
efficacy observed with DEF201 may be explained by a
combination of factors that includes constitutive expression of
fully glycosylated protein and reduced animal stress levels by
avoiding daily injections for 7–10 days. We hypothesize that with
the appropriate dose of DEF201, therapeutic levels of consensus
IFN-a can be maintained, effectively eliminating the daily bolus
effect produced by i.p. injections. In addition, because cIFN-a is
produced in genetically engineered Escherichia coli, the native
glycosylation pattern is lost. Conceivably, enhanced immunother-
apeutic activity results from fully glycosylated cIFN-a expressed
from cells transduced with DEF201.
Previous studies in mice with a related DEF201 virus expressing
mouse IFN-a (mDEF201) have shown the utility of adenovirus-
based system to counter viral infections [20,32,33]. More recently,
in a different hamster model of viral hemorrhagic fever, several of
us reported on efficacy of DEF201 in mitigating YFV infection
and disease [19]. YFV infection appears to be more sensitive to the
effects of DEF201, as a lower dose was able to provide complete
protection. Taken together with the results of the present study,
the experimental animal data support the broad use of DEF201
for extended pre-exposure and early post-exposure prophylaxis
applications. Further investigations using advanced arenavirus
models based on challenge of nonhuman primates with pathogenic
arenaviruses [17] are needed to better evaluate the potential of
DEF201 to prevent severe disease in humans. Nonhuman primate
models should allow the full spectrum of cIFN-a activity not
possible in hamsters or guinea pigs.
The familiarity of the FDA with adenovirus gene delivery
technology and approved cIFN-a protein support the development
of DEF201 for clinical use. An important step in the development
process is the safety/toxicology testing in rodents, which is presently
underway. In our studies, the highest dose of 10
8 pfu of DEF201
administered by the i.n. route appeared to be well-tolerated in
hamsters despite evidence of weight loss. They did not appear
visibly ill, but clearly the treatment was having some effect that
possibly led to reduced food and water consumption consistent with
mild toxicity seen with IFN-a therapy. The i.n. delivery route is
designed to circumvent pre-existing immunity to adenovirus type 5
in humans [21,34], and may limit systemic inflammation that could
Figure 5. Early DEF201 post-exposure-treatment protects
PICV-infected hamsters from mortality. Animals were treated
with a single i.n. dose of 10
8 pfu of DEF201 or the rAd EV control 24 h
prior to infection, or 6, 24, or 48 h post infection. The dashed lines
represent the 1
st and 2
nd challenges of the animals with PICV on day 0
and 28 of the experiment, respectively. For the initial infection,
**P,0.01, ***P,0.001 compared to respective rAd EV-treated controls.
For the second infection, sham-infected animals from the 1
st infection
were challenged with PICV and compared to groups of surviving
animals;
aP,0.05,
bP,0.01,
cP,0.001.
doi:10.1371/journal.pone.0026072.g005
Adenovirus Vectored IFN Averts Arenaviral Disease
PLoS ONE | www.plosone.org 6 October 2011 | Volume 6 | Issue 10 | e26072occur by parenteral administration of large numbers of adenovirus
particles. Ultimately, the production of a shelf-stable, powdered
formulation of DEF201 for easy i.n. administration and long-term
storage would be ideal for stock-piling in the event of the need for
mass distribution due to intentional release or (re)emerging disease
outbreaks of arena or other viral etiology.
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